BlackRock Fund Advisors recently announced the acquisition of new stake in TherapeuticsMD Inc. (NASDAQ:TXMD). The institutional investor has increased its shareholding in the Healthcare company by 11.76% to 18.27 million shares with purchase of 1.92 million shares. This fresh investment now brings its stake to 6.73% valued currently at $33.8 million. In addition, GMT Capital Corp. raised its holdings by 0.85 million to 5.99 million shares.
With over 2.04 million TherapeuticsMD Inc. (TXMD) shares trading Monday and a closing price of $1.46 on the day, the dollar volume was approximately $2.98 million. The shares have shown a negative weekly performance of -7.01% and its price on 08/31/20 lost nearly -2.01%. Currently, there are 271.88M common shares owned by the public and among those 238.66M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 9 analysts who have offered their price forecasts for TXMD have a consensus price objective of $6.90. The analysts have set the share’s price value over the next 12 months at a high of $13.00 and a low of $1.20 should the stock experience a downside. Incidentally, analysts’ outlook for the TherapeuticsMD Inc. stock is 2.20 for the next 12 months. But an upside of 88.77% will see the stock hit the forecast high price target while mean target price for the stock is $7.00.
Insiders at the company have transacted a total of 15 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 14 of these insider trades were purchases, accounting for 760,700 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 300,000 shares.
The top 3 mutual fund holders in TherapeuticsMD Inc. are T Rowe Price Small Cap Stock Fund, Fidelity Series Large Cap Stock F, and Vanguard Total Stock Market Index. T Rowe Price Small Cap Stock Fund owns 9.15 million shares of the company’s stock, all valued at over $16.93 million. The company sold 35300.0 shares recently to bring their total holdings to about 3.37% of the shares outstanding. Vanguard Total Stock Market Index now owns shares totaling to 2.48% of the shares outstanding.
Shares of TherapeuticsMD Inc. (NASDAQ: TXMD) opened at $1.49, unchanged from a prior closing price of $1.49. However, the script later closed the day at $1.46, down -2.01%. The company’s stock has a 5-day price change of -7.01% and 28.07% over the past three months. TXMD shares are trading -39.67% year to date (YTD), with the 12-month market performance down to -49.48% lower. It has a 12-month low price of $0.85 and touched a high of $4.32 over the same period. Currently, 2.04 million shares have been traded, compared to an average intraday trading volume of 5.08 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.33%, -9.59%, and -16.40% respectively.
Institutional ownership of TherapeuticsMD Inc. (NASDAQ: TXMD) shares accounts for 56.90% of the company’s 271.88M shares outstanding. Mutual fund holders own 24.14%, while other institutional holders and individual stakeholders account for 33.43% and 15.02% respectively.
It has a market capitalization of $386.86M and a beta (3y monthly) value of 2.11. The earnings-per-share (ttm) stands at -$0.72. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.65% over the week and 7.14% over the month.
Analysts forecast that TherapeuticsMD Inc. (TXMD) will achieve an EPS of -$0.14 for the current quarter, -$0.11 for the next quarter and -$0.31 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.14 while analysts give the company a high EPS estimate of -$0.13. Comparatively, EPS for the current quarter was -$0.13 a year ago. Earnings per share for the fiscal year are expected to decrease by -21.30%, and 51.60% over the next financial year. EPS should grow at an annualized rate of 21.80% over the next five years, compared to -14.60% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate TherapeuticsMD Inc. (TXMD) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 1 of the 9 advise that investors “hold,” and 1 rated it as a “Sell.”
Looking at the support for the TXMD, a number of firms have released research notes about the stock. Jefferies stated their Underperform rating for the stock in a research note on August 07, 2020, with the firm’s price target at. JP Morgan coverage for the TherapeuticsMD Inc. (TXMD) stock in a research note released on May 19, 2020 offered a Neutral rating with a price target of. Guggenheim was of a view on December 02, 2019 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on October 17, 2019, issuing a price target of $7. Noble Capital Markets on their part issued Outperform rating on April 30, 2019.